Clinical trial · no report yet · Phase 2/Phase 3
COMPANION-002
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
- NCT05506943 ↗
- Active, not recruiting
- Compass Therapeutics
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 8 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel Alone in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Who Have Received One Prior Systemic Chemotherapy Regimen
- Phase
- Phase 2/Phase 3
- Status
- Active, not recruiting
- Conditions
- Biliary Tract Cancer; Cholangiocarcinoma; Gall Bladder Cancer; Ampullary Cancer
- Interventions
- CTX-009; Paclitaxel
- Arms
- CTX-009 plus Paclitaxel · Experimental
- Paclitaxel · Active comparator
- Enrollment
- 168
- Primary outcomes
- Best Overall Response
- Sponsor
- Compass Therapeutics
- Start
- Jan 9, 2023
- Primary completion
- Aug 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05506943 · updated Sep 2, 2026
Publications
linked from the registry- Azad N, Hu Z, Sahin I, Iyer R, Aranha O, Hochster H, Pathak P, Paulson AS, Kalyan A, Liao CY, Tran N, Kelley RK, Heestand G, Cosgrove D, El-Khoueiry A, Borad M, Gabrail NY, Majeed U, Du L, Kamath S, Shumway N, Shroff R, Goyal L, Rosales M, Javle M. COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC. Future Oncol. 2024;20(30):2241-2248. doi: 10.1080/14796694.2024.2351351. Epub 2024 Jun 4. PubMed 38861293